Olfr813 Activators
Olfr813, also known as Olfactory Receptor 813, is a protein receptor found predominantly in the olfactory system of organisms. This receptor plays a crucial role in the sense of smell, particularly in detecting specific odorants and initiating the signaling cascade responsible for olfactory perception. The primary function of Olfr813 is to recognize and interact with odor molecules, thereby enabling the organism to discern and respond to its chemical environment. Activation of Olfr813 involves a complex set of molecular events that ultimately lead to the perception of odors. When an odorant molecule enters the nasal cavity and binds to Olfr813, it triggers a conformational change in the receptor protein. This conformational change is a pivotal step in the activation process, as it initiates a series of downstream events.
Upon binding of the odorant, Olfr813 activates a G-protein coupled receptor (GPCR) signaling pathway. The G-protein associated with Olfr813, when activated, initiates the release of intracellular messengers, such as cyclic adenosine monophosphate (cAMP). Increased cAMP levels then lead to the activation of protein kinase A (PKA), which, in turn, phosphorylates various downstream target proteins. These phosphorylation events contribute to the depolarization of olfactory sensory neurons, ultimately generating action potentials that are transmitted to the brain for odor perception. Furthermore, Olfr813's activation can also lead to the opening of ion channels, such as cyclic nucleotide-gated (CNG) channels. These channels allow the influx of ions like calcium and sodium, which further amplify the neuronal signals. The cumulative effect of these molecular events results in the transmission of signals to the brain's olfactory cortex, where the brain processes the information and interprets it as a specific odor.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin, from Coleus forskohlii, activates adenylate cyclase, thus increasing cAMP levels. Elevated cAMP can modulate GPCR signaling, potentially affecting Olfr813 activity by enhancing receptor phosphorylation and sensitivity through PKA-mediated pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol, a β-adrenergic agonist, raises intracellular cAMP via adenylate cyclase activation. Increased cAMP could indirectly modulate Olfr813 signaling pathways, enhancing receptor activation and signal transduction. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels, potentially influencing Olfr813 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine, an endogenous catecholamine, stimulates α and β-adrenergic receptors, boosting cAMP via adenylate cyclase. This surge in cAMP could indirectly affect Olfr813 activation, potentially enhancing its activity through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram, a phosphodiesterase 4 (PDE4) inhibitor, increases cAMP levels. Elevated cAMP may enhance Olfr813 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Cilostamide, a selective PDE3 inhibitor, raises intracellular cAMP, potentially influencing Olfr813 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $92.00 $138.00 | ||
Salbutamol, a β2-adrenergic agonist, raises cAMP levels via adenylate cyclase activation. This increase might boost Olfr813 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $31.00 $83.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr813 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr813 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr813 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy. | ||||||